Kimberly-Clark is laying down $40 billion to buy Kenvue in a massive deal that has puzzled some investors as the Tylenol maker struggles with weak sales, lawsuits and White House attacks linking its painkiller to autism.

Shares of Kimberly-Clark dropped sharply after the Monday announcement as stockholders scrutinized the 46% premium being paid for the former Johnson & Johnson unit that has had a turbulent year: Kenvue ousted its CEO in July and has been under fire from President Donald Trump over unproven claims that Tylenol use during pregnancy can cause autism in children.

Kenvue shares, which had dropped sharply since Trump's comments, jumped as much as 19.6% on Monday. Many investors have been awaiting a sale of all or parts of the company for months, following activist pressure

See Full Page